ADZA Adeza Biomedical (MM)

Adeza (Nasdaq:ADZA) today announced preliminary record product sales for the three months ended September 30, 2006 of approximately $13.5 million, an increase of $2.0 million or 17% from product sales of $11.5 million in the third quarter of 2005, and an increase of $0.5 million or 4% from product sales of $13.0 million in the second quarter of 2006. The company expects to achieve its 17th consecutive quarter of profitability on these record product sales. �We continue to see a large market opportunity for FullTerm�, the Fetal Fibronectin Test for assessing the risk of preterm birth. Our targeted marketing programs, the impact of increasing our sales force earlier this year and our expanded relationship with Quest Diagnostics that we announced in May are factors that we believe will continue to build our revenues,� said Emory V. Anderson, president and chief executive officer. Conference Call Adeza expects to report full financial results for the 2006 third quarter and to update 2006 financial guidance after market close on November 1, followed by an investment-community conference call beginning at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss these results, the Gestiva� regulatory status and to answer questions. Individuals interested in participating in the conference call may do so by dialing 888-463-4383 for domestic callers, or 706-634-5615 for international callers. A telephone replay will be available for 48 hours following the conclusion of the call by dialing 800-642-1687 for domestic callers, or 706-645-9291 for international callers, and entering reservation code 9490938. The live call also will be available via the Internet on the Investor Relations section of the company�s Web site at www.adeza.com. A webcast replay of the call will be available following the conclusion of the call. About Adeza Adeza designs, manufactures and markets innovative products for women's health. Adeza's initial focus is on reproductive healthcare using its proprietary technologies to predict preterm birth and assess infertility. Adeza's principal product is a patented diagnostic test, FullTerm, The Fetal Fibronectin Test, which utilizes a single-use, disposable cassette and is analyzed on Adeza's patented TLiIQ� System. This product is approved by the U.S. Food and Drug Administration (FDA) for use in assessing the risk of preterm birth. Adeza also markets and sells the E-tegrity� Test, an infertility-related test to assess receptivity of the uterus to embryo implantation in women with unexplained infertility. In May 2006, Adeza announced the submission of its New Drug Application (NDA) to the FDA for Gestiva, a long-acting form of a naturally occurring progesterone to prevent preterm birth in women with a history of preterm delivery, and on October 20, 2006 received an approvable letter from the FDA. More information is available at www.adeza.com. Adeza cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements, including for example, forecasts of future revenue and the bases for revenue growth. The inclusion of forward-looking statements should not be regarded as a representation by Adeza that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Adeza's business, including, without limitation, risks related to fluctuations in our business and market acceptance of our products. Further information about these and other risks is included Adeza�s Annual Report on Form 10-K and other periodic and current reports filed by Adeza with the Securities Exchange Commission, which are available from the SEC's Web site (www.sec.gov), and also available on the Investor Relations section of Adeza�s Web site. All forward-looking statements are qualified in their entirety by this cautionary statement and Adeza undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Adeza (Nasdaq:ADZA) today announced preliminary record product sales for the three months ended September 30, 2006 of approximately $13.5 million, an increase of $2.0 million or 17% from product sales of $11.5 million in the third quarter of 2005, and an increase of $0.5 million or 4% from product sales of $13.0 million in the second quarter of 2006. The company expects to achieve its 17th consecutive quarter of profitability on these record product sales. "We continue to see a large market opportunity for FullTerm(TM), the Fetal Fibronectin Test for assessing the risk of preterm birth. Our targeted marketing programs, the impact of increasing our sales force earlier this year and our expanded relationship with Quest Diagnostics that we announced in May are factors that we believe will continue to build our revenues," said Emory V. Anderson, president and chief executive officer. Conference Call Adeza expects to report full financial results for the 2006 third quarter and to update 2006 financial guidance after market close on November 1, followed by an investment-community conference call beginning at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss these results, the Gestiva(TM) regulatory status and to answer questions. Individuals interested in participating in the conference call may do so by dialing 888-463-4383 for domestic callers, or 706-634-5615 for international callers. A telephone replay will be available for 48 hours following the conclusion of the call by dialing 800-642-1687 for domestic callers, or 706-645-9291 for international callers, and entering reservation code 9490938. The live call also will be available via the Internet on the Investor Relations section of the company's Web site at www.adeza.com. A webcast replay of the call will be available following the conclusion of the call. About Adeza Adeza designs, manufactures and markets innovative products for women's health. Adeza's initial focus is on reproductive healthcare using its proprietary technologies to predict preterm birth and assess infertility. Adeza's principal product is a patented diagnostic test, FullTerm, The Fetal Fibronectin Test, which utilizes a single-use, disposable cassette and is analyzed on Adeza's patented TLiIQ(R) System. This product is approved by the U.S. Food and Drug Administration (FDA) for use in assessing the risk of preterm birth. Adeza also markets and sells the E-tegrity(R) Test, an infertility-related test to assess receptivity of the uterus to embryo implantation in women with unexplained infertility. In May 2006, Adeza announced the submission of its New Drug Application (NDA) to the FDA for Gestiva, a long-acting form of a naturally occurring progesterone to prevent preterm birth in women with a history of preterm delivery, and on October 20, 2006 received an approvable letter from the FDA. More information is available at www.adeza.com. Adeza cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements, including for example, forecasts of future revenue and the bases for revenue growth. The inclusion of forward-looking statements should not be regarded as a representation by Adeza that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Adeza's business, including, without limitation, risks related to fluctuations in our business and market acceptance of our products. Further information about these and other risks is included Adeza's Annual Report on Form 10-K and other periodic and current reports filed by Adeza with the Securities Exchange Commission, which are available from the SEC's Web site (www.sec.gov), and also available on the Investor Relations section of Adeza's Web site. All forward-looking statements are qualified in their entirety by this cautionary statement and Adeza undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.